SEP 13, 2017 09:00 AM PDT
How Biomarker Testing Shapes Immunotherapy
Presented at the Microbiology & Immunology 2017 Virtual Event
SPONSORED BY: Vela Diagnostics
CONTINUING EDUCATION (CME/CE/CEU) CREDITS: P.A.C.E. CE | Florida CE
1 1 34

Speakers:
  • Vice President of Precision Oncology, Vela Dx
    Biography
      Condie Carmack, Ph.D. received his Ph.D. from the University of Utah in Experimental Pathology and did postdocs in Philadelphia, PA and San Diego, CA. in mouse genetics and molecular biology. He is the author or or co-author of 23 peer-reviewed journal. He wrote the first paper on quantitative PCR and the second paper on multiplex PCR. He served on the Science Advisory Board of Life Technologies Inc. as an expert in clinical PCR. He was co-author on the first paper creating human monoclonal antibodies from immunodeficient mice. Mice serve as the foundation for creation of the current immune checkpoint blockade antibodies such as ipilimumab and nivolumab. He also served as General Manager of the Cancer Genetics Lab at Baylor College of Medicine before joining Vela Diagnostics

    Abstract:

    The immune system is complex and dynamic, focused on defending the body from a host of pathogens ranging from viruses to cancer. A number of different mechanisms have evolved that help the body fight to control cancers and other disease. Unfortunately, sometimes these defenses break down and become compromised, enabling cancers to survive and grow within the host.

    Recent breakthroughs have shown that Immunotherapeutic approaches may be successful in helping the host's immune system battle cancer, providing the body with ways to protect itself from cancer.  Key to making this work is an understanding of both who will benefit from the therapy and at what stage in disease progression the therapy will be effective.  In our discussion we will look at how biomarker development can aide in addressing these challenges.  We will cover:

    •    Overview of Immunotherapies & their mechanisms of action
    •    Biomarkers associated with Immunotherapies
    •    Biomarker clinical testing
    •    Immunotherapy adverse reactions & success stories 


    Show Resources
    Loading Comments...